Staff Writer Noxxon Pharma AG has concluded a $2 million financing, as part of a $35 million Series D financing that will fund development of its three development programs to proof of concept...NOX-A12, aimed at autologous stem cell transplantation in hematological disorders, has been evaluated in models of stem cell mobilization, angiogenesis, inflammation and lung and kidney injury...The first-in-human clinical trial for NOX-A12 was successfully completed in May in healthy individuals following

Advanced Cell Technology Inc., of Marlborough, Mass., completed Phase I trials in more than 40 patients testing its myoblast stem cell therapy in heart failure, advanced heart failure, myocardial infarction and ischemia...Results also demonstrated statistically significant improvements in clinical symptom scores and reductions in the incidence of bronchiolitis obliterans syndrome...Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, initiated their second Phase III trial of MDV3100

Cerulean Pharma Inc., of Cambridge, Mass., reported results of a Phase I clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and preclinical data on Cerulean's development candidate, CRLX288, at the American Chemical Society National Meeting & Exposition, ongoing in Boston

Cardio3 BioSciences SA, of Mont-Saint-Guibert, Belgium, reported results showing that its heart failure stem cell therapy C-Cure showed positive and encouraging trends in a number of physiological and clinical parameters, including meaningful differences in ventricular size, ejection fraction and other measures of heart muscle activity in C-Cure-treated patients when compared to control and to baseline...Tranzyme Pharma Inc., of Research Triangle Park, N.C., said its ghrelin agonist TZP-102

Pro-Cure, which develops drugs targeted against cancer stem cells, plans to take its lead candidate, a monoclonal antibody, into the clinic in prostate cancer by the end of 2012.

Horizon Pharma Inc., of Northbrook, Ill., reported interim results from a pilot clinical study showing that Lodotra (modified-release prednisone tablet) chronotherapy might improve asthma control and asthma-related quality of life when added to standard asthma therapy in patients with severe nocturnal asthma...The first clinical study, to be funded by the National Institute of Allergy and Infectious Disease, will enroll 72 healthy adult volunteers to receive injections of placebo, a lower dose or a

Proceeds will be used to support working capital and expand its stem cell product development projects, including additional projects ongoing at its subsidiaries Embryome Sciences Inc., OncoCyte Corp., BioTime Asia Ltd...A portion of the funds might also be used to start clinical trials for new indications for lead product Hextend, including severe malaria...Funds will be used for working capital needs, including the ongoing clinical development of MN-221 in acute exacerbations of asthma and chronic

Stem Cell Therapeutics Corp., of Calgary, Alberta, disclosed the receipt of approval from the TSX Venture Exchange to extend the expiry date of the 50-cent warrants issued in conjunction with a financing dated Nov. 9, 2007, from May 9, 2010, to June 30, 2010.

Stem cells were separated from the adipose tissue utilizing the fully automated TGI 1200 Cell Isolation System...The recovered stem cells were injected into the patients' hearts utilizing Bioheart's MyoCath needle injection catheter

Stem Cell Therapeutics Corp., of Calgary, Alberta, said Phase IIa data showed that stroke drug NTx-265 was found to be safe, with patients showing improved clinical outcomes compared to published data on similar untreated stroke patients, as well as a trend toward reduced infarct volumes over time in comparison to data previously described elsewhere

QR Pharma Inc., of Radnor, Pa., started a trial of lead compound Posiphen in early stage Alzheimer's disease patients...The stem cells were administered by direct injection into the brain of a patient with connatal PMD, the most severe form of the disease...This marks the first time that neural stem cells have been transplanted as a potential treatment for a myelination disorder, and the second clinical trial involving the use of HuCNS-SC cells in a neurodegenerative disease, the company said

But those stories will have to show meaningful clinical results and clear value-creating milestones, he noted...The drug has attracted lucrative partnerships with Forest Laboratories Inc., Astellas Pharma Inc...Viroblock also appointed Jamie Paterson, former chief commercial officer at Neurim Pharmaceuticals Ltd., as CEO.

China Pharma Holdings Inc., of Haikou City, China, said that it has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production application to China's FDA...trial to evaluate human neural stem cells for the treatment of ALS

California Stem Cell Inc., of Irvine, Calif., has completed a Series B financing round with private investors, the amount of which was not disclosed...The financing will support the advancement of its therapeutic products to clinical trials, as well as the generation and distribution of its tools to aid in stem cell research and drug discovery

patients receiving autologous stem cell transplants each year, with two years of treatment potential, additional revenues in the out years could reach up to $900 million...MAPLight.org's research previously has shown alignment of pharma campaign money and votes in Congress

Advaxis will contribute the study drug and some funds to the cost of the trial, including the translational clinical immunology research...BioAlliance Pharma SA, of Paris, gained approval from the French drug agency to start a Phase II trial of clonidine Lauriad in radiotherapy- and chemotherapy-induced oral mucositis...Cardio3 BioSciences SA, of Mont-Saint-Guibert, Belgium, completed enrollment ahead of schedule in the first stage of its pivotal Phase II/III trial of C-Cure, a stem cell therapy for

Kiadis Pharma BV, of Amsterdam, the Netherlands, enrolled the first patient in its registration study of ATIR, which is designed to show reduction in transplant-related mortality after one year following an allogeneic stem cell transplantation with a mismatched donor in blood cancer patients who are eligible for a transplant but do not have a matched donor available

Proceeds will fund a Phase III combination Reolysin and paclitaxel/carboplatin trial with platinum-failed head and neck cancers, as well as other clinical and R&D activities and general corporate purposes...The company expects to use the net proceeds of about $7.3 million to focus on regulatory and partnering activities for picoplatin, clinical development, other general corporate purposes and working capital...Those funds will be used for business development activities and other general corporate

The clinical trial, titled "CopperProof 2," will test the effects of a gastro-retentive, sustained-release zinc/cysteine combination tablet on the amelioration of subclinical zinc deficiency, and elevated percentage serum-free copper, associated with Alzheimer's disease...Noxxon Pharma AG, of Berlin,, has begun dosing healthy volunteers in a first-in-human trial with Spiegelmer NOX-A12 for use in autologous hematopoietic stem cell transplantation in patients with non-Hodgkin's lymphoma or multiple